Nautilus Biotechnology, Inc.

Good morning, ladies and gentlemen. Thank you for standing by. And welcome to Nautilus Biotechnology fourth quarter 2021 earnings conference call. At this time, all participants are on a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press the star, then the one key on your touchtone telephone. If you recall operating systems at any time, please press star, then zero. I would now like to hand the conference over to your speaker host. Alex Scott of Investor Relations.

Thank you. Earlier today, Nautilus released financial results for the quarter and full year ended December 31, 2021. If you haven't received this news release or if you'd like to be added to the company's distribution list, please send an email to investorrelations at nautilus.bio. Joining me today from Nautilus are Sugil Patel, co-founder and CEO, Parag Malik, co-founder and chief scientist, and Anna Mowry, chief financial officer. Before we begin, I'd like to remind you the management will make statements during this call that are forward-looking within the meaning of the federal securities laws. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated. Additional information regarding these risks and uncertainties appears in the section entitled Forward-Looking Statements in the press release Nautilus issued today. Except as required by law, Nautilus disclaims any intention or obligation to update or revise any financial or product pipeline projections or other forward-looking statements, whether because of new information, future events, or otherwise. This conference call contains time-sensitive information and is accurate only as of the live broadcast, February 24, 2022. With that, I'll turn the call over to Sujal.

Thanks, Alex. Good morning, and thank you to everyone for joining us on the call. Today, we will review our results for the fourth quarter and full year 2021 and provide an update on a range of recent activities. Since our last call, we've continued to make strong progress against our key scientific and business goals due to the efforts of our incredible teams in the Bay Area and Seattle. Bringing any game-changing innovation to the market requires not just a great idea, but a team willing to do what it takes to succeed. I'm very proud of the way our team has risen to the challenge and embraced the opportunity through focus, intensity, and a deep sense of scientific curiosity to provide ubiquitous access to the proteome for every lab, researcher, and clinician around the world. To begin, I want to take a moment to remind everyone of our broader mission. When I speak with potential customers, partners, and key opinion leaders, I continue to hear an increasingly common refrain. The primary role they see for innovative next-gen proteomics is to drive revolutionary improvements in drug discovery, diagnostics, and human health in the decades to come. There's no doubt in my mind that Nautilus will be a leader in this vibrant and valued space. For many years, we've been told that a wave of precision and personalized medicines based on the intricate details of each patient's biology is just over the horizon. Unfortunately, except for niche cases like drugs targeting specific mutations in cancer cells or genome editing for rare diseases, this wave has not come. This is perhaps because our hopes for personalized medicine have been primarily tied to advances in genetics and genomics. Yet, as we all know, while genomes help us understand general susceptibilities, they do little to inform people about the state of their current health or if their lifestyle choices or environmental factors have increased or decreased their disease risk. Proteomics technologies like Nautilus, on the other hand, aim to reveal stateful information telling us what's happening right now. As proteins carry out the majority of cellular function, the dynamic patterns of these ever-changing proteomic profiles comprising thousands to millions of protein variations can reveal whether we're healthy, sick, or have greater potential to become sick. These same proteins can help us individualize our treatments based on what's happening in our body today and what has been happening throughout our lifetime. We fully believe that proteomics is a critical ingredient in making personalized medicine a reality. The reach and impact of Nautilus' innovation is potentially immense. Recent estimates are that the proteomics market is approximately $25 billion and growing at a 12% CAGR. While this opportunity is an immediate and exciting area of focus for us, we believe that technologies that improve accessibility and reproducibility and deliver faster turnaround time with reduced complexity, like Nautilus, will be the catalyst to expand this market opportunity. Simply put, our goal is to democratize proteomics, and in doing so, revolutionize biological science. We expect that researchers in biomedicine, regardless of their background, will be able to use our technologies, and as Parag and I have both said before, we hope to make it possible for anyone who wants a proteome to get a proteome. Nautilus' widely accessible proteomics platform aims to dramatically accelerate target identification and drug development. Using it, we expect researchers will be able to establish proteomes for any sample they wish, ranging from tissue culture model systems to preclinical serine tissues to human clinical samples. With these in hand, it will be easier to figure out how disease processes have impacted our body and to create drugs that target the molecular underpinnings of each disease and with fewer side effects. We continue to see a broad array of users for our instrument. From researchers in biopharma and academic institutions to clinical practitioners, we believe our instrument will fit the needs of a wide range of proteomics users. Among those groups, The common thread will be their need to dig deeper and more quickly into proteins and proteoforms of interest. We believe that Nautilus will enable them to develop more effective therapeutics, to build more precise diagnostics, and to pick the best therapy for a particular patient. As we start 2022, we are more confident than ever that the single molecule protein measurement platform that we're building will deliver value to biological researchers in a way that's simply not possible through any other method. We're excited to have you along on this journey and look forward to updating you on our progress along the way. I'll now turn the call over to Parag for an update on our research and development and partnership activities. Parag.